Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03277482 · ClinicalTrials.gov registry record · Phase 1
Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer
A Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Terminated
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT03277482 is a Phase 1 study that was terminated before completion, run by Dana-Farber Cancer Institute. The registered enrollment target is 16 participants.
The verdict
NCT03277482, a Phase 1 study, was terminated before completion, sponsored by Dana-Farber Cancer Institute.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This research study is evaluating the safety and effectiveness of 2 immunotherapy drugs in combination with radiation therapy as a possible treatment for recurrent or metastatic gynecologic cancer. The names of the immunotherapy drugs involved in this study are: * Durvalumab * Tremelimumab
Interventions
- RADIATION Radiation Therapy
- DRUG Durvalumab
- DRUG Tremelimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2018-06-01 |
| Est. Completion | 2022-07-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03277482
The ClinicalTrials.gov registry entry for NCT03277482 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Radiation Therapy is the first listed.
NCT03277482 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03277482 about?
NCT03277482 is a clinical study titled "Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer". This research study is evaluating the safety and effectiveness of 2 immunotherapy drugs in combination with radiation therapy as a possible treatment for recurrent or metastatic gynecologic cancer. The names of the immunotherapy drugs involved in this study are: * Durvalumab * Tremelimumab
What is the current status of trial NCT03277482?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2018-06-01. Estimated completion is 2022-07-15.
What interventions are being tested in trial NCT03277482?
The interventions under investigation include: Radiation Therapy (RADIATION), Durvalumab (DRUG), Tremelimumab (DRUG).
Who is sponsoring clinical trial NCT03277482?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.